Interest continues to grow in the use of microbes to produce cannabinoids.
Intrexon, an American biotech company listed on the Nasdaq stock exchange, has announced a development in its microbial platform capable of producing cannabinoids for medical use.
It has created a yeast strain capable of producing low-cost, robust and consistent cannabinoid outputs through fermentation.
Exectuve directive Chris Savile said: “Microbial fermentation routes to produce cannabinoids provide advantages over traditional plant-based extraction. We expect to optimise strains to produce specific cannabinoids that may be commercialised in the coming years.”

Read full article
I'm already a subscriber

Freddie Dawson

Managing editor, news
Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the ECigIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization